Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
Vesper Medical will further expand Philips’ portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease
Scoliosis is a disorder of the spine, and its surgeries are generally done only in large hospitals in big cities.
It is a novel oral NLRP3 inflammasome inhibitor
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Subscribe To Our Newsletter & Stay Updated
